JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced ...
In the ongoing Omicron era, a new Covid-19 antibody could renew optimism for urgently required SARS-CoV-2 monoclonal therapies. Over the last three years, various ...
Study reveals early immune responses to SARS-CoV-2, offering insights for future COVID-19 treatments
In a recent study published in the journal Nature, a group of researchers analyzed early cellular response dynamics to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in seronegative ...
From Wednesday to Thursday the World Health Organization reported an additional 47 cases and one death from Severe Acute Respiratory Syndrome. This brings the total to 2,270 cases and 79 deaths in 16 ...
The Social Security Administration (SSA) provides disability benefits to people living with disabilities through two programs: Social Security Disability Insurance (SSDI) and Supplemental Security ...
In this ongoing, randomized, phase 3 trial, sotrovimab (a SARS-CoV-2–targeted monoclonal antibody) or placebo was administered to outpatients within 5 days after the onset of Covid-19 symptoms. The ...
JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results